| Primary |
| Systemic Lupus Erythematosus |
26.4% |
| Rheumatoid Arthritis |
25.5% |
| Drug Use For Unknown Indication |
9.6% |
| Connective Tissue Disorder |
4.8% |
| Product Used For Unknown Indication |
4.8% |
| Cutaneous Sarcoidosis |
4.3% |
| Sjogren's Syndrome |
3.4% |
| Cutaneous Lupus Erythematosus |
2.4% |
| Dermatitis Herpetiformis |
2.4% |
| Hypertension |
2.4% |
| Asthma |
1.9% |
| Hypercholesterolaemia |
1.9% |
| Dermatomyositis |
1.4% |
| Malignant Melanoma Of Sites Other Than Skin |
1.4% |
| Prophylaxis |
1.4% |
| Q Fever |
1.4% |
| Type 2 Diabetes Mellitus |
1.4% |
| Angioedema |
1.0% |
| Arthralgia |
1.0% |
| Dyspepsia |
1.0% |
|
| Vomiting |
10.4% |
| Toxic Epidermal Necrolysis |
7.5% |
| Electrocardiogram Qt Prolonged |
6.0% |
| Posterior Reversible Encephalopathy Syndrome |
6.0% |
| Sick Sinus Syndrome |
6.0% |
| Urticaria |
6.0% |
| Weight Decreased |
6.0% |
| Weight Increased |
6.0% |
| Myopathy Toxic |
4.5% |
| Pigmentation Disorder |
4.5% |
| Rash Pruritic |
4.5% |
| Skin Lesion |
4.5% |
| Status Epilepticus |
4.5% |
| Ventricular Fibrillation |
4.5% |
| Ventricular Hypertrophy |
4.5% |
| Abdominal Discomfort |
3.0% |
| Cardiomyopathy |
3.0% |
| Cutaneous Lupus Erythematosus |
3.0% |
| Dyspnoea |
3.0% |
| Histoplasmosis |
3.0% |
|
| Secondary |
| Rheumatoid Arthritis |
28.9% |
| Product Used For Unknown Indication |
25.7% |
| Systemic Lupus Erythematosus |
15.8% |
| Cutaneous Sarcoidosis |
5.0% |
| Lupus Nephritis |
4.0% |
| Drug Use For Unknown Indication |
3.5% |
| Hypertension |
2.3% |
| Non-small Cell Lung Cancer |
2.2% |
| Dermatomyositis |
1.7% |
| Pain |
1.5% |
| Drug Exposure During Pregnancy |
1.3% |
| Hypercholesterolaemia |
1.2% |
| Pancreatic Carcinoma Metastatic |
1.1% |
| Polyarthritis |
1.1% |
| Connective Tissue Disorder |
1.0% |
| Interstitial Lung Disease |
0.8% |
| Glaucoma |
0.7% |
| Osteoporosis |
0.7% |
| Pulmonary Fibrosis |
0.7% |
| Suicide Attempt |
0.7% |
|
| Teratogenicity |
11.4% |
| Completed Suicide |
9.5% |
| Vomiting |
8.6% |
| Basal Cell Carcinoma |
7.6% |
| Liver Function Test Abnormal |
6.7% |
| Thrombocytopenia |
5.7% |
| Drug Abuse |
4.8% |
| Rash |
4.8% |
| Treatment Failure |
4.8% |
| Urinary Tract Infection |
4.8% |
| Angioedema |
3.8% |
| Drug-induced Liver Injury |
3.8% |
| Toxicity To Various Agents |
3.8% |
| Cardiac Arrest |
2.9% |
| Colitis |
2.9% |
| Device Related Sepsis |
2.9% |
| Drug Hypersensitivity |
2.9% |
| Epidural Lipomatosis |
2.9% |
| Impaired Healing |
2.9% |
| Mycobacterial Infection |
2.9% |
|
| Concomitant |
| Product Used For Unknown Indication |
33.6% |
| Rheumatoid Arthritis |
32.2% |
| Drug Use For Unknown Indication |
9.3% |
| Systemic Lupus Erythematosus |
5.1% |
| Hypertension |
3.3% |
| Pain |
2.8% |
| Arthritis |
1.7% |
| Vitamin Supplementation |
1.4% |
| Depression |
1.4% |
| Osteoporosis |
1.3% |
| Gastrooesophageal Reflux Disease |
1.1% |
| Diabetes Mellitus |
1.0% |
| Blood Cholesterol Increased |
0.9% |
| Fibromyalgia |
0.9% |
| Hypersensitivity |
0.8% |
| Hypothyroidism |
0.8% |
| Psoriatic Arthropathy |
0.7% |
| Anxiety |
0.7% |
| Lupus Nephritis |
0.6% |
| Pulmonary Arterial Hypertension |
0.6% |
|
| Injection Site Pain |
11.3% |
| Rheumatoid Arthritis |
8.8% |
| Vomiting |
8.6% |
| Weight Decreased |
7.0% |
| Weight Increased |
6.4% |
| Drug Ineffective |
5.9% |
| Injection Site Swelling |
4.8% |
| Pain |
4.8% |
| Systemic Lupus Erythematosus |
4.5% |
| Pneumonia |
4.3% |
| Pain In Extremity |
4.2% |
| Urinary Tract Infection |
4.2% |
| Sinusitis |
3.8% |
| Nausea |
3.4% |
| Rash |
3.4% |
| Sepsis |
3.4% |
| Pyrexia |
3.2% |
| Injection Site Warmth |
2.9% |
| Death |
2.7% |
| Headache |
2.6% |
|
| Interacting |
| Q Fever |
88.9% |
| Autoimmune Disorder |
5.6% |
| Tuberculosis |
5.6% |
|
| Psychotic Disorder |
66.7% |
| Toxic Skin Eruption |
33.3% |
|
